Skip to Content
Radiation Research Program
Contact NExT
Show menu
Search this site
Last Updated: 10/06/21

Preclinical Chemo-Radiotherapy Testing Consortium

PCRTC U01 Program


The Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC) consists of specialized U01 research projects focused around the shared goal of testing of NCI-prioritized molecularly targeted anti-cancer agents from the CTEP collection ( that best sensitize tumor cells to standard of care chemoradiation therapies. PCRTC teams were funded through PAR 16-111 To Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy ( to investigate NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity when combined with chemo-radiotherapy. These pre-clinical studies accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors, with concentration on cancers of the pancreas, lung, head and neck, gastrointestinal tract, and brain.

PCRTC Projects

Institution (primary site) MPI Contact Project Title
UNIVERSITY OF MICHIGAN AT ANN ARBOR THEODORE S. LAWRENCE Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response
MASSACHUSETTS GENERAL HOSPITAL HENNING WILLERS High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizerse
MAYO CLINIC ROCHESTER JANN N. SARKARIA Pre-Clinical Novel Radiosensitizer Evaluation Program for Brain Tumorse
UNIVERSITY OF TX MD ANDERSON CAN CTR STEVEN HSESHENG LIN Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches

PCRTC Publications

Members of Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC) organized to present viewpoints on enabling new clinical trial concepts in cancer through pre-clinical testing of radiation-drug combinations. The series published in the International Journal of Radiation Oncology-Biology-Physics (see links below) focuses on models and validation methodologies developed through the PCRTC.

Buchsbaum JC, Coleman CN, Bernhard EJ, Espey MG, Vikram B. Overview and Lessons From the Preclinical Chemoradiotherapy Testing Consortium. Int J Radiat Oncol Biol Phys. 2021 Aug 1:S0360-3016(21)02622-5. doi: 10.1016/j.ijrobp.2021.07.1709. Epub ahead of print. PMID: 34348172.

Lin SH, Willers H, Krishnan S, Sarkaria JN, Baumann M, Lawrence TS. Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. Int J Radiat Oncol Biol Phys. 2021 Aug 25:S0360-3016(21)02706-1. doi: 10.1016/j.ijrobp.2021.08.018. Epub ahead of print. PMID: 34454045.

Ye R, Qiao Y, Singh PK, Wang Y, He J, Li N, Krishnan S, Lin SH. High-Content Clonogenic Survival Screen to Identify Chemoradiation Sensitizers. Int J Radiat Oncol Biol Phys. 2021 Aug 2:S0360-3016(21)02625-0. doi: 10.1016/j.ijrobp.2021.07.1712. Epub ahead of print. PMID: 34348174.

Willers H, Pan X, Borgeaud N, Korovina I, Koi L, Egan R, Greninger P, Rosenkranz A, Kung J, Liss AS, Parsels LA, Morgan MA, Lawrence TS, Lin SH, Hong TS, Yeap BY, Wirth LJ, Hata AN, Ott CJ, Benes CH, Baumann M, Krause M. Screening and Validation of Molecular Targeted Radiosensitizers. Int J Radiat Oncol Biol Phys. 2021 Jul 31:S0360-3016(21)02585-2. doi: 10.1016/j.ijrobp.2021.07.1694. Epub ahead of print. PMID: 34343607.

Dragojevic S, Ji J, Singh PK, Connors MA, Mutter RW, Lester SC, Talele SM, Zhang W, Carlson BL, Remmes NB, Park SS, Elmquist WF, Krishnan S, Tryggestad EJ, Sarkaria JN. Preclinical Risk Evaluation of Normal Tissue Injury With Novel Radiosensitizers. Int J Radiat Oncol Biol Phys. 2021 Aug 14:S0360-3016(21)02642-0. doi: 10.1016/j.ijrobp.2021.08.003. Epub ahead of print. PMID: 34400266.

Parsels LA, Zhang Q, Karnak D, Parsels JD, Lam K, Willers H, Green MD, Rehemtulla A, Lawrence TS, Morgan MA. Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic. Int J Radiat Oncol Biol Phys. 2021 Aug 1:S0360-3016(21)02621-3. doi: 10.1016/j.ijrobp.2021.07.1708. Epub ahead of print. PMID: 34348175.